UNSPSC 51385613: Aspirin aluminium

This classification denotes a cyclooxygenase inhibitor with the molecular formula 2C9H7O4.Al.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E33TS05V6B, chemically known as aluminium, bis(2-(acetyloxy)benzoato-.kappa.o)hydroxy-, but more generally known as aspirin aluminium, which bears US NIH Compound Identifier 3032790. European Medicines Agency schedules aspirin aluminium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20435.

Most nations, for tariff purposes, schedule aspirin aluminium under HS 29182200. SMILES: CC(=O)OC1CCCCC1C(=O)[O-].CC(=O)OC1CCCCC1C(=O)[O-].[OH-].[AL+3].

UNSPSC 51385613 Aspirin aluminium is a Commodity code that encompasses pharmaceutical and over-the-counter (OTC) products state and local governments procure for public health, community health, and employee benefit programs. Recent solicitations show state and local buyers acquiring generic pharmaceuticals, branded OTC medications, and specialized health products through both direct purchase and cooperative purchasing frameworks. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances serving state agencies, local governments, and school districts across multiple jurisdictions. Procurement typically requires compliance with cGMP certification, Drug Supply Chain Security Act (DSCSA) standards, FDA approval, and established insurance coverages; vendors must often work through authorized pharmaceutical wholesalers and maintain electronic data interchange (EDI) capability to support supply chain integration.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct-contracting models and outcomes-based pricing alternatives to traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to serve participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract pricing weighted 75 percent on competitiveness, 10 percent on fixed pricing stability, and 5 percent each on EDI capability, administrative fee compliance, and data format requirements.